Simon R Procter
Overview
Explore the profile of Simon R Procter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
751
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goncalves B, Lykke M, Cutland C, Horvath-Puho E, Bijlsma M, Procter S
Int J Epidemiol
. 2025 Feb;
54(1).
PMID: 39903877
No abstract available.
2.
Procter S, Waterlow N, Radhakrishnan S, van Leeuwen E, Meeyai A, Cooper B, et al.
BMJ Glob Health
. 2024 Nov;
9(11).
PMID: 39557448
Introduction: Thailand was one of the first low- and middle-income countries to publicly fund seasonal influenza vaccines, but the lack of predictability in the timing of epidemics and difficulty in...
3.
Procter S, Paul P, Horvath-Puho E, Goncalves B
Int J Epidemiol
. 2024 Jun;
53(3).
PMID: 38847782
Background: Maternal colonization by the bacterium Group B streptococcus (GBS) increases risk of preterm birth, a condition that has an important impact on the health of children. However, research studies...
4.
5.
Trotter C, Alderson M, Dangor Z, Ip M, Le Doare K, Nakabembe E, et al.
Vaccine
. 2023 Nov;
41 Suppl 2:S41-S52.
PMID: 37951694
Group B streptococcus (GBS) is a major global cause of neonatal meningitis, sepsis and pneumonia, with an estimated 91,000 infant deaths per year and an additional 46,000 stillbirths. GBS infection...
6.
Waterlow N, Procter S, van Leeuwen E, Radhakrishnan S, Jit M, Eggo R
Vaccine
. 2023 Aug;
41(41):6017-6024.
PMID: 37633749
Next generation influenza vaccines are in development and have the potential for widespread health and economic benefits. Determining the potential health and economic impact for these vaccines is needed to...
7.
Waterlow N, Procter S, Eggo R, Jit M
BMC Med
. 2023 Aug;
21(1):301.
PMID: 37559086
We recently published an article in BMC Medicine looking at the potential health and economic impact of paediatric vaccination using next-generation influenza vaccines in Kenya: a modelling study. In their...
8.
Auzenbergs M, Fu H, Abbas K, Procter S, Cutts F, Jit M
Lancet Glob Health
. 2023 Jul;
11(8):e1194-e1204.
PMID: 37474227
Background: WHO recommends at least 95% population coverage with two doses of measles-containing vaccine (MCV). Most countries worldwide use routine services to offer a first dose of measles-containing vaccine (MCV1)...
9.
Sorano S, Procter S, Seale A
Vaccine X
. 2023 Jul;
14:100332.
PMID: 37441365
Background: Group B Streptococcus (GBS) is a leading pathogen causing life-threatening bacterial infections in neonates (early- or late-onset) and infants, and is associated with preterm and stillbirth. Japan introduced national...
10.
Ruiz F, Torres-Rueda S, Pearson C, Bergren E, Okeke C, Procter S, et al.
PLOS Glob Public Health
. 2023 Mar;
3(3):e0001693.
PMID: 36963054
While safe and efficacious COVID-19 vaccines have achieved high coverage in high-income settings, roll-out remains slow in sub-Saharan Africa. By April 2022, Nigeria, a country of over 200 million people,...